Response Evaluation Criteria

Related by string. * re sponse . Responses . RESPONSE : Computer Emergency Response . Emergency Response Team . Community Emergency Response / evaluations . Evaluations . EVALUATION : undergo psychiatric evaluation . undergoing psychiatric evaluation / CRITERIA . criterias : Downgrade Criteria June . Common Criteria certification * RECIST Response Evaluation Criteria *

Related by context. Frequent words. (Click for all words.) 82 RECIST criteria 79 RECIST 74 Solid Tumors 68 evaluable patients 68 evaluable 68 cytogenetic response 66 neoadjuvant chemotherapy 66 immunohistochemical 65 breast carcinoma 64 plus dexamethasone 64 DAS# [002] 64 annualized relapse 63 neoadjuvant 63 mg kg dose 63 estimated glomerular filtration 63 FOLFIRI 63 dasatinib 63 Secondary endpoints include 62 Secondary endpoints 62 neoadjuvant therapy 62 sustained virologic response 62 mycophenolate mofetil 62 FDG PET 62 peripheral blood mononuclear 62 cardiac dysfunction 62 chemoradiotherapy 62 complete remissions 62 HER2 positive metastatic breast 61 composite endpoint 61 peginterferon alfa 2a 61 median PFS 61 free survival PFS 61 FOLFOX 61 interferon alfa 60 plus prednisone 60 mg BID 60 peg IFN 60 nomogram 60 HERmark 60 PRECiSE 60 histologic 60 estrogen receptor ER 60 noninferiority 60 creatinine clearance 60 xenograft models 60 Arch Intern Med 60 ANOVA 60 mg QD 60 IMGN# 60 peginterferon 59 EORTC 59 Secondary endpoints included 59 antibody titers 59 metastatic renal cell carcinoma 59 eGFR 59 pertuzumab 59 mcg kg 59 castration resistant prostate cancer 59 COPAXONE R 59 Disease Activity 59 Pharmacokinetic 59 nab paclitaxel 59 malignant lesions 59 Chronic Lymphocytic Leukemia 59 azacitidine 59 plus ribavirin 59 glioblastoma multiforme GBM 59 XELOX 59 sensitivity specificity 59 febrile neutropenia 59 virologic response 59 dacarbazine 59 serum concentrations 58 relapsed multiple myeloma 58 Gynecologic Oncology Group 58 HER2 negative 58 fluorouracil 58 tumor shrinkage 58 Ph + ALL 58 chemoradiation 58 J Am Coll 58 Irinotecan 58 nephrectomy 58 epithelial ovarian cancer 58 adalimumab 58 EBRT 58 glomerular filtration rate 58 metastatic hormone refractory 58 Fludara 58 histopathological 58 decitabine 58 relapsed refractory multiple myeloma 58 oral glucose tolerance 58 carotid intima media 58 pharmacodynamic effects 58 proteinuria 58 mRNA expression 58 Median survival 58 microalbuminuria 58 Lenalidomide 58 D dimer

Back to home page